Home/Pipeline/Merck TRACTr Program 1

Merck TRACTr Program 1

Undisclosed

Phase 1Active (Partnered)

Key Facts

Indication

Undisclosed

Phase

Phase 1

Status

Active (Partnered)

Company

Janux Therapeutics

About Janux Therapeutics

Janux Therapeutics is on a mission to transform cancer and autoimmune disease treatment by developing precision-engineered, tumor-activated immunotherapies that maximize efficacy and safety. Founded in 2017, the company has rapidly advanced its proprietary TRACTr and TRACIr platforms, moving multiple programs into clinical development and securing high-value partnerships with Merck and Bristol Myers Squibb. Its strategy centers on solving the critical therapeutic index challenge in immuno-oncology, aiming to expand the utility of potent T-cell redirecting therapies into solid tumors, a vast and underserved market.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases

Other Undisclosed Drugs

Drug	Company	Phase	Status
Preclinical ISAC 1	Bolt Biotherapeutics	Preclinical	Available for Partnering
Preclinical ISAC 2	Bolt Biotherapeutics	Preclinical	Available for Partnering
ART12.11	Artelo Biosciences	Preclinical	Active
Novel Vaccines	MSD	Development	Active
SLS-009	Seelos Therapeutics	Discovery	Research
Measovir®-based Prophylactic Vaccine (with Unither)	Oncovita	Research/Pre-clinical	Early-stage collaboration
Internal sdAb Discovery Program	NanoTag Biotechnologies	Discovery	Active
Amgen Collaboration Program	Xeris Biopharma	Pre-clinical	Active
NB-701	Nerai Biosciences	Discovery	Active
Undisclosed Therapeutic Program(s)	Bright Cell	Clinical Trial (Phase unspecified)	Active
Biosimilars Pipeline	Intelligent Therapeutics	Pre-clinical/Development	Active
Proprietary Therapeutic Pipeline	Excelsior Sciences	Discovery	Active